NYCDoc29

@SrihariNaiduMD @purviparwani @baileyannRN @docbhardwaj @JamalRanaMD @seiiwaiEPmd @DNFeldmanMD @adityadoc1 @djc795 @CMichaelGibson @LindsayLuvDavis Happy Father’s Day! I know the journey!

My friends know I’ve been a single dad via divorce since ‘Kiri’ was 2. Realized fast there’s no mom or dad there’s just (if lucky) someone who loves, guides & protects you with pure heart. Here’s to fathers, mothers & all the rest in that role! Ps teen boys squirm out of pics! 😆

CONGRESS #EHA2024 | Primary analysis of the phase II ELM-2 study demonstrates deep and durable responses with odronextamab (CD20×CD3 bispecific antibody) in heavily pretreated pts with R/R FL. Primary endpoint ORR, 80%; CR rate 73%; CR correlated with favorable PFS and OS at 24 mo. Patients with low/undetectable CD20 expression achieved CR. CRS events were mostly low grade. #lymphoma #lymsm #MedicalCongress

very impressive so far #mmsm #myeloma #EHA24 #EHA2024 $ACLX

Impressive PFS with the quadruplet combination in NTEMM…but balancing efficacy and tolerability is key in the elderly. Great plenary presentation by Prof Facon #EHA2024

Galtier - outcome of PMBCL with CAR-T (Descar-T data) - 55 axi-cel pts - 80% CMR - 2y PFS 68.7% - CRP > 30 prognostic - LDH / briding response NOT prognostic Excellent outcomes! Encouraging. #EHA2024 #lymsm

CONGRESS #EHA2024 | Arnon P. Kater @amsterdamumc shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=35, mFU=8.1 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), OS was 11.7 mo, non-hematologic TEAEs were of mainly low grade (Gr 1-2). CRS was mostly low grade. #lymphoma #lymsm #leusm #medicalcongress #hematology

Glofitamab monotherapy as salvage therapy in heavily pretreated mantle cell #lymphoma With @amniebla as chair-@WomenInLymphoma of the session! 💪 @geltamo #EHA2024

@OmarNadeemMD nice to see another option beside talquetamab #myeloma #mmsm #EHA24 - would love to see future development in trials tease out "differences"

#EHA24, Bories Pierre Real world data on elderly>75 with CAR-t versus younger.<75 Bias of selection likely but as good as for younger. So we can treat also the old 😊 increased risk of infections!!

Do check out our multicentre collaboration from 🇨🇦 at #EHA24 👍🏼 Belumosudil shows promise in treating patients with heavily pre-treated moderate-severe cGVHD. Median of 5 prior lines of Rx (all Rux exposed) Median of 3 affected organs at start of Rx FFS 6m: 72% #EHA24

taken along with TRANSFORM-1 looks like single agent JAK2i maybe out in frontline MF. #EHA24 #MPN

@rajshekharucms wonder IF a subgroup of patients drove results? high-risk cytogenetics? subsequent #CART treatment? #EHA24 #MMSM #myeloma

CASSIOPEIA 7-yr update: Does Dara maintenace add benefit pts who receive Dara-based induction? New data suggest a marginal benefit, but note heavy censoring beyond 5 yrs! Will this hold up in DR vs R? My take: I remain skeptical of Dara in Mx pending GMMG-HD7/DRAMMATIC! #EHA24

@doctorpemm @EHA_Hematology @harrisoncn1 @mpdrc @jjkiladjian @RaajitRampal @PedsHemeDoc @mpndoc @KuykendallMd @GabyHobbs @mtmdphd @mdmajmudar @KMirza Will single agent JAK2i be out? TRANSFORM-1 looks like it will "transform" MF treatment in frontline. #EHA24 #MPNSM $INCY

👉👉👉Honored to present #EHA24 #EHA2024 today 👉#TRANSFORM-1 results randomized ph3 clinical trial. RUXO+#NAVITOCLAX frontline vs RUXO+placebo n=252, Med f/u 20.3 mo. SVR35w24= 63.2% NaV+RuXo vs 31.5% in RUXO+PLCBO ➡️Primary Endpoint met| #MPNSM @EHA_Hematology @harrisoncn1

Always nice to see long-term follow up results! Dr. Moreau pointed out that >80% of patients in Dara-VTD arm of CASSIOPEIA are alive at 8 years despite half of them getting no maintenace! Exciting prospects indeed for limited duration therapy in #MultipleMyeloma! #EHA24

#EHA2024 #EHA24 #MPN_PV Palandri: state of the art talk on PV 1) 4 must-dos in all pts. 2) timely intervention, moving to 2nd line therapy appropriately, nice algorithm 👇🏽 3) Role of hepcidin analogues.

@amarkelkar @marklewismd its more politics - state boards are filled with appointees by governor. NO governor wants to lose this additional influence over #healthcare - its a place to reward supporters

@marklewismd It’s a problem we as physicians historically helped create through state medical boards as an anti-competitive measure. I am for going to national licenses and national telehealth, but I think we need to convince our own community … there’s also risk to private practices.

The rollback of telehealth after the height of the pandemic signifies a regulatory erasure of one silver lining of how we adapted care delivery (necessity being the mother of invention) In a country as geographically vast as the US, it allows us to REACH more patients! #ASCO24

#MedTwitter - licensing currently is state issued & controlled by state boards which are highly political. Nobody wants to ceed their fief & governors don't want to lose control. #telehealth

LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO ➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️ ➡️ 24-mo PFS: 65% vs 13% 📈 ➡️ 81% received osi at progression 💊, Good! ➡️AE discontinuation**: 13% vs 5% ⚠️ Can't wait for @RamalingamMD's presentation today! 🎤 #ASCO24 @OncoAlert Data courtesy: @FordePatrick’s tweet! @OncoAlert